Release Date: 2024-05-28

Urine Biomarkers for Bladder Cancer

Ahmet Keles (Author)

Release Date: 2024-05-28

Urine biomarkers for bladder cancer, explored in this chapter, assess their potential in enhancing diagnostic accuracy, monitoring recurrence, and improving surveillance protocols. The chapter discusses various biomarkers like EpiCheckTM, Xpert® Bladder Cancer Monitor, ADX BladderTM, and Cxbladder, evaluating their sensitivity and specificity for detecting high-grade tumors and their integration into clinical practice as adjuncts or [...]

Media Type

  • PDF

Buy from

Price may vary by retailers

Work TypeBook Chapter
Published inCurrent Management of Non-Muscle Invasive Bladder Cancer
First Page69
Last Page75
DOIhttps://doi.org/10.69860/nobel.9786053359197.5
ISBN978-605-335-919-7 (PDF)
LanguageENG
Page Count7
Copyright HolderNobel Tıp Kitabevleri
Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

Urine biomarkers for bladder cancer, explored in this chapter, assess their potential in enhancing diagnostic accuracy, monitoring recurrence, and improving surveillance protocols. The chapter discusses various biomarkers like EpiCheckTM, Xpert® Bladder Cancer Monitor, ADX BladderTM, and Cxbladder, evaluating their sensitivity and specificity for detecting high-grade tumors and their integration into clinical practice as adjuncts or alternatives to traditional methods like cystoscopy.

Ahmet Keles (Author)
Istanbul Medeniyet University
https://orcid.org/0000-0001-5436-1803
3Dr. Ahmet Keles earned his Doctor of Medicine (MD) degree from Akdeniz University School of Medicine and completed his residency in residency in the Department of Urology at Marmara University Faculty of Medicine. During his residency, he achieved certification in European Basic Laparoscopic Urological Skills (E-BLUS) and became a Fellow of the European Board of Urology (FEBU). To further specialize, Dr. Keles underwent rigorous endourology training under Prof. Dr. Jean de la Rosette at Amsterdam Academic Medical Center (AMC) through the prestigious European Urological Scholarship Programme (EUSP). Currently, he is expanding his expertise as a Urologist at Istanbul Medeniyet University Faculty of Medicine. Dr. Keles’s research has resulted in nearly 30 scientific publications in peer-reviewed journals and numerous presentations at national and international conferences. Additionally, he has contributed to the field by authoring six book chapters in urology and oncology. He is also a member of the European Association of Urology (EAU) and the American Urological Association (AUA).

  • 1. Wéber A, Vignat J, Shah R, Morgan E, Laversanne M, Nagy P, Kenessey I, Znaor A. Global burden of bladder cancer mortality in 2020 and 2040 according to GLOBOCAN estimates. World J Urol. 2024 Apr 16;42(1):237.

  • 2. Contieri R, Hensley PJ, Tan WS, Grajales V, Bree K, Nogueras-Gonzalez GM, Lee BH, Navai N, Dinney CP, Kamat AM. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive BladderCancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. Eur Urol Oncol. 2023 Dec;6(6):590-596.

  • 3. D’Andrea D, Soria F, Zehetmayer S, Gust KM, Korn S, Witjes JA, Shariat SF. Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer. BJU Int. 2019 Jun;123(6):959-67.

  • 4. Ribal MJ, Mengual L, Lozano JJ, Ingelmo-Torres M, Palou J, Rodríguez-Faba O, Witjes JA, Van der Heijden AG, Medina R, Conde JM, Marberger M, Schmidbauer J, Fernández PL, Alcaraz A. Gene expression test for the non-invasive diagnosis of bladder cancer: A prospective, blinded, international and multicenter validation study. Eur J Cancer. 2016 Feb;54:131-138.

  • 5. Beukers W, van der Keur KA, Kandimalla R, Vergouwe Y, Steyerberg EW, Boormans JL, Jensen JB, Lorente JA, Real FX, Segersten U, Orntoft TF, Malats N, Malmström PU, Dyrskjot L, Zwarthoff EC. FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study. J Urol. 2017 Jun;197(6):1410-18.

  • 6. Rouprêt M, Gontero P, McCracken SRC, Dudderidge T, Stockley J, Kennedy A, Rodriguez O, Sieverink C, Vanié F, Allasia M, Witjes JA, Colombel M, Longo F, Montanari E, Palou J, Sylvester RJ. Reducing the Frequency of Follow-up Cystoscopy in Low-grade pTa Non-muscle-invasive Bladder Cancer Using the ADXBLADDER Biomarker. Eur Urol Focus. 2022 Nov;8(6):1643-1649

  • 7. Cancel-Tassin G, Roupret M, Pinar U, Gaffory C, Vanie F, Ondet V, Compérat E, Cussenot O. Assessment of Xpert Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up. World J Urol. 2021 Sep;39(9):3329-3335.

  • 8. Gontero P, Montanari E, Roupret M, Longo F, Stockley J, Kennedy A, Rodriguez O, McCracken SRC, Dudderidge T, Sieverink C, Vanié F, Allasia M, Witjes JA, Sylvester R, Colombel M, Palou J. Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non-muscle-invasive bladder cancer: a blinded prospective multicentric study. BJU Int. 2021 Feb;127(2):198- 204.

  • 9. Dudderidge T, Stockley J, Nabi G, Mom J, Umez-Eronini N, Hrouda D, Cresswell J, McCracken SRC. A Novel, non-invasive Test Enabling Bladder Cancer Detection in Urine Sediment of Patients Presenting with Haematuria-A Prospective Multicentre Performance Evaluation of ADXBLADDER. Eur Urol Oncol. 2020 Feb;3(1):42-46.

  • 10. Laukhtina E, Shim SR, Mori K, D’Andrea D, Soria F, Rajwa P, Mostafaei H, Compérat E, Cimadamore A, Moschini M, Teoh JY, Enikeev D, Xylinas E, Lotan Y, Palou J, Gontero P, Babjuk M, Witjes JA, Kamat AM, Roupret M, Shariat SF, Pradere B; European Association of Urology–Young Academic Urologists (EAUYAU): Urothelial Carcinoma Working Group. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. Eur Urol Oncol. 2021 Dec;4(6):927-42

  • 11. Palermo M, D’Elia C, Trenti E, Comploj E, Mian C, Schwienbacher C, Heidegger I, Clauser S, Pycha A, Vjaters E. Prospective evaluation of the RT-PCR based urinary marker Bladder Epicheck® as a diagnostic tool in upper urinary tract tumor. Minerva Urol Nephrol. 2024 Apr;76(2):195-202.

  • 12. Wallace E, Higuchi R, Satya M et al (2018) Development of a 90-minute integrated noninvasive urinary assay for bladder cancer detection. J Urol 199:655–662

  • 13. O’Sullivan P, Sharples K, Dalphin M, Davidson P, Gilling P, Cambridge L, Harvey J, Toro T, Giles N, Luxmanan C, Alves CF, Yoon HS, Hinder V, Masters J, Kennedy-Smith A, Beaven T, Guilford PJ. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. J Urol. 2012 Sep;188(3):741-7.

  • 14. Sathianathen NJ, Butaney M, Weight CJ, Kumar R, Konety BR. Urinary Biomarkers in the Evaluation of Primary Hematuria: A Systematic Review and Meta-Analysis. Bladder Cancer. 2018 Oct 29;4(4):353-363.

onix_3.0::thothThoth ONIX 3.0
onix_3.0::project_museProject MUSE ONIX 3.0
onix_3.0::oapenOAPEN ONIX 3.0
onix_3.0::jstorJSTOR ONIX 3.0
onix_3.0::google_booksGoogle Books ONIX 3.0
onix_3.0::overdriveOverDrive ONIX 3.0
onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
csv::thothThoth CSV
json::thothThoth JSON
kbart::oclcOCLC KBART
bibtex::thothThoth BibTeX
doideposit::crossrefCrossRef DOI deposit
onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
marc21record::thothThoth MARC 21 Record
marc21markup::thothThoth MARC 21 Markup
marc21xml::thothThoth MARC 21 XML

Share This Chapter!